new
coronaviru
recent
emerg
caus
human
pandem
wherea
molecular
diagnost
test
rapidli
develop
serolog
assay
still
lack
yet
urgent
need
valid
serolog
assay
import
contact
trace
identifi
viral
reservoir
epidemiolog
studi
develop
serolog
assay
detect
neutral
spikeand
nucleocapsidspecif
antibodi
use
serum
sampl
patient
pcrconfirm
infect
coronavirus
respiratori
pathogen
infect
valid
test
variou
antigen
differ
inhous
commerci
elisa
demonstr
pcrconfirm
infect
individu
seroconvert
reveal
sensit
specif
inhous
elisa
found
commerci
igg
iga
elisa
lower
specif
sensit
vari
two
iga
show
higher
sensit
overal
valid
assay
describ
instrument
detect
antibodi
diagnost
seroepidemiolog
vaccin
evalu
studi
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
decemb
new
coronaviru
cov
emerg
china
caus
acut
respiratori
diseas
known
coronaviru
diseas
viru
identifi
betacoronaviru
relat
sever
acut
respiratori
syndrom
coronaviru
sarscov
thu
name
less
two
decad
viru
third
known
coronaviru
cross
speci
barrier
caus
sever
respiratori
infect
human
follow
sarscov
middl
east
respiratori
syndrom
yet
unpreced
spread
compar
earlier
two
due
rapid
rise
number
case
uncontrol
vast
worldwid
spread
declar
pandem
march
viru
infect
individu
countri
fatal
outcom
rapid
identif
etiolog
share
genet
sequenc
viru
follow
intern
collabor
effort
initi
due
emerg
led
rapid
avail
realtim
pcr
diagnost
assay
support
case
ascertain
track
outbreak
avail
help
patient
detect
effort
contain
viru
howev
specif
valid
serolog
assay
still
lack
moment
urgent
need
understand
epidemiolog
valid
serolog
assay
crucial
patient
contact
trace
identifi
viral
reservoir
host
epidemiolog
studi
epidemiolog
studi
urgent
need
help
uncov
burden
diseas
particular
rate
asymptomat
infect
get
better
estim
morbid
mortal
addit
epidemiolog
studi
help
reveal
extent
viru
spread
household
commun
specif
set
could
help
guid
control
measur
serolog
assay
also
need
evalu
result
vaccin
trial
develop
therapeut
antibodi
among
four
coronaviru
structur
protein
spike
nucleocapsid
n
main
immunogen
describ
develop
serolog
assay
detect
viru
neutral
antibodi
antibodi
nucleocapsid
n
protein
variou
spike
domain
includ
subunit
receptor
bind
domain
rbd
elisa
format
use
wellcharacter
cohort
serum
sampl
pcrconfirm
patient
pcrconfirm
infect
season
coronavirus
respiratori
pathogen
valid
test
variou
antigen
differ
platform
develop
inhous
well
commerci
platform
serum
sampl
collect
pcrconfirm
mild
sever
patient
tabl
franc
accord
local
ethic
approv
sampl
use
assay
valid
person
pcrdiagnos
infect
human
coronavirus
sar
mer
rang
respiratori
virus
tabl
publish
previous
sampl
patient
recent
cmv
ebv
mycoplasma
pneumonia
infect
includ
higher
likelihood
caus
fals
posit
result
use
serum
sampl
healthi
blood
donor
cohort
neg
control
sanquin
blood
bank
rotterdam
netherland
obtain
written
inform
consent
research
use
sampl
store
use
use
serum
sampl
netherland
approv
local
medic
ethic
committe
mec
approv
serum
sampl
sar
patient
kindli
provid
professor
malik
peiri
hong
kong
univers
serum
sampl
pcrconfirm
case
n
previous
analyz
recombin
spike
proteinbas
immunofluoresc
test
plaqu
reduct
neutral
et
al
submit
manuscript
doi
http
sera
test
part
extend
diagnost
regimen
upon
inform
written
consent
patient
sera
stem
serum
collect
nation
consiliari
laboratori
coronaviru
detect
berlin
germani
provid
diagnost
propos
upon
inform
written
consent
collect
contain
followup
sera
pcrconfirm
human
case
merscov
sarscov
common
cold
cov
antibodi
posit
sera
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
spike
ectodomain
residu
strain
genbank
sarscov
residu
strain
genbank
merscov
residu
strain
emc
genbank
express
cell
ctermin
trimer
motif
streptag
use
pcagg
express
plasmid
likewis
subunit
subdomain
residu
residu
rbd
residu
genbank
express
cell
prnt
use
refer
studi
neutral
assay
standard
cov
serolog
test
serum
sampl
neutral
capac
german
isol
gisaid
id
epiisl
european
viru
archiv
global
plaquereduct
neutral
test
prnt
previous
describ
modif
heatinactiv
sampl
serial
dilut
dmem
medium
supplement
hepe
buffer
penicillin
streptomycin
fetal
bovin
serum
start
dilut
fifti
viru
suspens
spot
form
unit
ad
well
incub
h
follow
incub
mixtur
ad
cell
incub
hour
cell
wash
incub
medium
h
incub
cell
fix
stain
polyclon
rabbit
antisarscov
antibodi
sino
biolog
cell
fix
stain
use
rabbit
antisarscov
serum
secondari
peroxidaselabel
goat
antirabbit
igg
dako
signal
develop
use
precipit
form
tmb
substrat
true
blue
kpl
number
infect
cell
per
well
count
use
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
imag
analyz
ctl
europ
gmbh
serum
neutral
titer
reciproc
highest
dilut
result
infect
reduct
titer
consid
posit
prnt
german
sera
done
describ
previous
use
vero
cell
hour
supernat
discard
cell
wash
pb
supplement
avicel
solut
dmem
day
plate
fix
inactiv
use
formaldehydepb
solut
stain
crystal
violet
perform
igg
iga
elisa
use
betavers
two
commerci
kit
euroimmun
medizinisch
labordiagnostika
ag
http
wwweuroimmuncom
perform
assay
accord
manufactur
protocol
reagent
well
assay
coat
recombin
structur
protein
domain
optic
densiti
od
detect
nm
ratio
read
sampl
read
calibr
includ
kit
calcul
sampl
od
ratio
betavers
kit
await
ce
valid
determin
inhous
cutoff
valu
base
mean
background
reactiv
sera
studi
multipli
case
iga
od
ratio
igg
od
ratio
perform
inhous
elisa
coat
microtit
elisa
plate
inhous
produc
spike
antigen
sarscov
merscov
rbd
protein
sarsn
sinobiolog
pb
overnight
follow
block
dilut
serum
serial
dilut
titer
ad
incub
antigenspecif
antibodi
detect
use
peroxidaselabel
rabbit
antihuman
igg
dako
http
wwwagilentcom
tmb
substrat
absorb
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
sampl
measur
nm
set
cutoff
standard
deviat
mean
valu
neg
cohort
serum
sampl
previous
test
antibodi
differ
coronavirus
describ
earlier
correl
antibodi
respons
detect
differ
elisa
detect
prnt
gold
standard
cov
serolog
analyz
use
graphpad
prism
version
http
wwwgraphpadcom
evalu
specif
antibodi
respons
sever
mild
case
use
serum
sampl
collect
differ
time
postdiseas
onset
three
french
pcrconfirm
patient
test
sera
specif
antibodi
use
differ
elisa
follow
infect
three
patient
seroconvert
day
post
onset
diseas
figur
antibodi
elicit
subunit
includ
ntermin
domain
receptor
bind
domain
rbd
sinc
n
protein
similar
sarscov
tabl
use
sarscov
n
antigen
test
ndirect
antibodi
elisa
format
found
follow
infect
antibodi
elicit
n
protein
test
prnt
assay
sera
abl
neutral
observ
crossreact
sarscov
protein
lower
extent
merscov
protein
merscov
protein
figur
gh
evid
analyz
degre
similar
differ
cov
protein
domain
correspond
protein
tabl
sarscov
show
high
similar
differ
domain
analysi
show
spike
subunit
conserv
among
cov
thu
play
role
crossreact
seen
whole
use
antigen
thu
specif
antigen
serolog
diagnosi
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
assess
specif
assay
use
cohort
ae
tabl
compris
sera
healthi
blood
donor
pcrconfirm
acut
respiratori
noncov
infect
b
acut
convalesc
pcrconfirm
alphaand
betahcov
infect
c
pcrconfirm
merscov
sarscov
e
infect
none
sera
specif
cohort
ad
reactiv
inhous
elisa
set
cutoff
indic
specif
wherea
sera
sarscov
patient
crossreact
figur
addit
specif
antigen
serolog
support
fact
cohort
ac
sera
includ
studi
seroposit
endem
hcov
determin
protein
microarray
figur
nonetheless
seroneg
sarscov
merscov
use
cohort
also
valid
specif
antinucleocapsid
antirbd
igg
elisa
detect
specif
antibodi
set
cutoff
except
sarscov
patient
sera
none
control
sera
test
posit
antirbd
antinucleocapsid
antibodi
figur
c
wherea
detect
seroconvers
among
three
patient
valid
elisa
differ
antigen
use
epidemiolog
studi
well
evalu
vaccineinduc
immun
respons
next
valid
sensit
specif
commerci
elisa
kit
detect
igg
iga
antibodi
use
cohort
figur
three
patient
reactiv
antibodi
igg
serum
sampl
iga
serum
sampl
elisa
figur
sarscov
patient
sera
reactiv
note
earlier
also
detect
reactiv
serum
sampl
valid
cohort
ad
iga
igg
elisa
two
patient
sera
reactiv
igg
iga
elisa
kit
confirm
crossreact
two
sera
test
twelv
serum
sampl
patient
collect
differ
time
point
preand
infect
preinfect
sera
neg
postinfect
sera
reactiv
igg
iga
base
elisa
earlier
report
crossreact
sera
merscov
igg
elisa
kit
valid
also
done
differ
laboratori
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
well
merscov
sarscov
infect
person
collect
day
post
diseas
onset
figur
patient
previous
confirm
seroconvert
day
post
onset
diseas
use
recombin
immunofluoresc
test
prnt
seroconvert
patient
show
reactiv
implement
cutoff
valu
igg
iga
elisa
one
patient
figur
black
line
maintain
slightli
cutoff
might
explain
overal
reduc
antibodi
respons
patient
overal
igabas
elisa
kit
sensit
less
specif
igg
base
elisa
kit
final
compar
perform
differ
elisa
detect
antibodi
among
pcrconfirm
patient
prnt
gold
standard
cov
serolog
tabl
correl
strongli
differ
elisa
commerci
iga
show
strongest
correl
follow
n
elisa
indic
capac
detect
specif
antibodi
howev
larger
patient
cohort
need
assess
sensit
platform
valid
serolog
assay
current
lack
yet
urgent
need
contact
trace
epidemiolog
vaccin
evalu
studi
sinc
n
protein
main
immunogen
cov
protein
develop
elisabas
assay
abl
detect
antibodi
two
protein
along
two
spike
domain
rbd
correl
strongli
viru
neutral
antibodi
detect
assay
sinc
major
human
popul
antibodi
four
endem
human
coronavirus
crucial
verifi
specif
assay
avoid
fals
posit
result
addit
two
zoonot
coronavirus
sarscov
merscov
also
betacoronavirus
rais
potenti
crossreact
among
spike
protein
antigen
test
specif
detect
antibodi
merscov
crossreact
antibodi
detect
serum
one
patient
seen
merscov
use
test
could
explain
high
degre
conserv
cov
subunit
rel
tabl
therefor
consist
earlier
find
merscov
serolog
specif
antigen
diagnost
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
test
specif
rbd
detect
antibodi
none
sera
form
valid
cohort
ae
show
reactiv
except
sarscov
patient
sera
notunexpect
crossreact
result
high
degre
similar
rbd
sarscov
tabl
howev
sarscov
circul
human
popul
sinc
ie
year
ago
earlier
studi
report
wane
sarscovspecif
antibodi
made
undetect
serum
sampl
sampl
test
year
follow
infect
therefor
unlik
antibodi
viru
present
popul
thu
could
hardli
chanc
fals
posit
result
sarscovantibodi
reactiv
meanwhil
made
use
high
degre
similar
sarscov
protein
develop
inhous
n
elisa
use
sarscov
n
similar
antigen
nelisa
could
detect
antibodi
high
specif
sensit
use
three
differ
valid
elisa
found
antibodi
level
higher
follow
sever
infect
compar
mild
one
similar
find
report
earlier
merscov
howev
need
confirm
larger
cohort
patient
vari
degre
sever
still
highlight
potenti
need
sensit
assay
avoid
miss
milder
infect
epidemiolog
studi
among
inhous
elisa
test
rbd
n
elisa
sensit
elisa
detect
antibodi
mildli
infect
patient
show
stronger
correl
titer
therefor
detect
antibodi
two
differ
antigen
might
need
confirm
find
avoid
fals
neg
surveil
studi
howev
sensit
assay
need
valid
larger
cohort
valid
betavers
iga
igg
commerci
elisa
two
differ
lab
igabas
elisa
show
higher
sensit
iggbas
elisa
opposit
true
specif
igg
elisa
specif
iga
elisa
yet
note
cross
reactiv
elisa
serum
sampl
two
patient
cross
react
merscov
igg
elisa
despit
differ
antigen
coat
indic
respons
anoth
protein
could
block
coat
matrix
apart
specif
antigen
coat
result
consist
fals
posit
result
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
overal
assay
develop
valid
studi
could
instrument
patient
contact
trace
serosurveil
studi
well
vaccin
evalu
studi
howev
sinc
variou
studi
carri
differ
lab
crucial
calibr
standard
assay
develop
differ
lab
use
well
defin
standard
refer
part
diagnost
assay
valid
need
reduc
interassay
variabl
also
harmon
result
obtain
differ
lab
use
variou
assay
crucial
better
comparison
interpertaion
result
differ
studi
well
evalu
vaccin
trial
allow
uniform
assess
immunogen
efficaci
better
understand
correl
immun
protect
thu
set
refer
panel
vital
element
prepared
approach
emerg
virus
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
protein
sequenc
align
use
clustalw
n
nucleocapsid
spike
ntermin
subunit
spike
protein
ctermin
subunit
spike
protein
domain
spike
subunit
rbd
receptor
bind
domain
nd
done
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
p
valu
summari
ns
nonsignific
p
reflect
signific
level
p
p
p
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
figur
kinet
antibodi
respons
follow
infect
test
one
sever
red
two
mild
green
black
patient
antibodi
respons
spike
b
spike
subunit
c
spike
ntermin
domain
receptor
bind
domain
e
nucleocapsid
protein
use
elisa
f
viru
neutral
antibodi
test
use
plaqu
reduct
neutral
assay
prnt
reactiv
sera
form
three
patient
differ
time
point
whole
spike
g
h
sarscov
merscov
test
elisa
sarscov
sever
acut
respiratori
syndrom
coronaviru
merscov
middl
east
respiratori
syndrom
coronaviru
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
kinet
antibodi
respons
three
patient
c
crossreact
sera
commerci
platform
e
f
correl
antibodi
respons
detect
elisa
plaqu
reduct
neutral
assay
g
h
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
figur
sensit
two
commerci
elisa
detect
specif
igg
c
e
iga
b
f
antibodi
kinet
antibodi
respons
patient
germani
b
correl
antibodi
respons
detect
elisa
plaqu
reduct
neutral
assay
c
e
f
kit
test
specif
serum
sampl
hcov
well
merscov
sarscov
infect
person
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
